title: Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
abstract: The survival of patients with multiple myeloma (MM) has improved substantially since the introduction in the late 1980s of high-dose chemotherapy (HDT) supported by autologous stem cell transplantation (ASCT). Further improvements have been observed following the availability of immunomodulatory drugs (IMiD) such as thalidomide and lenalidomide, and the proteasome inhibitor, bortezomib. Here, we summarise the recommendations of the Medical Scientific Advisory Group to the Myeloma Foundation of Australia for patients considered suitable for HDT + ASCT as part of initial therapy. These recommendations incorporate the various phases of treatment: induction, HDT conditioning and maintenance therapy.
authors.affiliation: Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.
authors.forename: H
authors.initials: H
authors.lastname: Quach
authors.forename: D
authors.initials: D
authors.lastname: Joshua
authors.forename: J
authors.initials: J
authors.lastname: Ho
authors.forename: J
authors.initials: J
authors.lastname: Szer
authors.forename: A
authors.initials: A
authors.lastname: Spencer
authors.forename: S J
authors.initials: SJ
authors.lastname: Harrison
authors.forename: P
authors.initials: P
authors.lastname: Mollee
authors.forename: A W
authors.initials: AW
authors.lastname: Roberts
authors.forename: N
authors.initials: N
authors.lastname: Horvath
authors.forename: D
authors.initials: D
authors.lastname: Talaulikar
authors.forename: B
authors.initials: B
authors.lastname: To
authors.forename: A
authors.initials: A
authors.lastname: Zannettino
authors.forename: R
authors.initials: R
authors.lastname: Brown
authors.forename: L
authors.initials: L
authors.lastname: Catley
authors.forename: B
authors.initials: B
authors.lastname: Augustson
authors.forename: W
authors.initials: W
authors.lastname: Jaksic
authors.forename: J
authors.initials: J
authors.lastname: Gibson
authors.forename: H M
authors.initials: HM
authors.lastname: Prince
mesh_terms: D026683:Advisory Committees; D001315:Australia / Q000453:epidemiology; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000592:standards*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000453:epidemiology; D017410:Practice Guidelines as Topic; D012958:Societies, Scientific; D015996:Survival Rate / Q000639:trends; D014182:Transplantation, Autologous; D016896:Treatment Outcome
keywords: multiple myeloma; stem cell transplant; therapy